Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

3D-Printed core-shell tablet for effective oral delivery of AT-MSC secretome in inflammatory bowel disease therapy.

Munoz-Perez E., Santos-Vizcaino E., Goyanes A., Basit AW., Hernandez RM.

Laboratory Study on Immune Modulation, published in Drug Deliv Transl Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Drug Deliv Transl Res (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40781489
DOI
10.1007/s13346-025-01932-7

Abstract (original English)

The complexity of inflammatory bowel disease (IBD) and its pharmacological management has driven research to explore novel treatment options for this condition. Among the emerging therapies, Mesenchymal Stromal Cells (MSCs) have proven to be effective, showing strong immunomodulatory properties. However, the efficiency of direct MSC administration has been questioned due to their short half-life and risk of rejection. As an alternative, MSCs secretome, containing the beneficial paracrine effectors of MSCs, is being explored as a promising cell-free therapeutic tool. However, the oral delivery of this secretome is complex and presents a significant technological challenge. Additionally, the personalization of secretome-based therapies is essential, as it is a costly treatment that requires dose customization for each patient. This study introduces a novel approach for the oral delivery of adipose-tissue derived MSC secretome (AT-S) using 3D-printed core-shell tablets. Remarkably, lyophilized secretome (LpAT-S) was used during the study to improve the manageability and stability of the secretome. The 3D printed system proved to be capable of protecting secretome proteins from gastric degradation, offering an unprecedented possibility for the oral administration of secretome therapies. Overall, this study shows that 3D printing offers a promising, patient-friendly solution for the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansInflammatory Bowel DiseasesAdministration, OralMesenchymal Stem CellsTabletsSecretomePrinting, Three-DimensionalAdipose TissueCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research